AJX

0.00%

1.3¢ alexium international group limited

Share Price Calculation, page-3

First 3 Last

Share
Profile

Follow
Pixie2000

731 Posts.

24

05/03/16

13:26

Post #: 17196388
Share

Originally posted by Inductor ↑

I have been looking at the share price conversations over the last week, and trying to put together a simple picture of what it should be compared to where it sits at the moment using the P/E ratio. I work in the technical world; my mastery of accounting is about the same as my grasp of Mandarin, so if somebody could drag out their green pen and audit my figures, I would be grateful.

Alexium is at the stage in its life where the share price represents as much of the sizzle as it does of the sausage, and to get some idea as to where we are, we have to use forward projections, rather than trailing figures.

Taking the recently released CY16 forward projection baseline figures:

Revenue: $18.5M

Margin: 30-60% (let’s take the middle – 45% after tax profit)

Shares: 286M

Earnings: 18.5M x 45% = 8.325M

EPS: 8.325M/286M = $0.029

An established company with a small growth rate has an average P/E ratio of 15, giving us a share price of 43.5c; our current share price gives a P/E of around 20.

Some forms of P/E analysis seem to use the growth rate as a multiplier in the ratio in companies like AJX (so a growth rate of 25% should give a P/E ratio of 25). Alexium’s growth rate is expected to be far higher than this, but what is the actual growth rate we should be looking at? The second half of last year was over 900% according to the figures, so that is clearly not a useful number in this context. The expected explosive nature of AJX may preclude this from being a reasonable form of estimate, but if we throw a growth rate of 25% in there, the share price should be around 72.5c.

From the above, it seems a 60c share price seems to be the compromise we have reached with Mr Market, where the sausage is in, but the sizzle has been damped down for the moment, as people absorb the information provided in the half yearly reports.

Comments, anybody?

Expand

All your figures are in USD. So then divide by the exchange rate

AJX Price at posting: 59.5¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

BUX

Buxton projects new graphite province discovery at WA Narryer play

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

There are more pages in this discussion • 110 more messages in this thread...

First 3 Last

Add AJX (ASX) to my watchlist

(20min delay)
Last 1.3¢		Change 0.000(0.00%)		Mkt cap ! $20.46M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
1	42000	1.2¢

Sellers (Offers)

Price($)	Vol.	No.
1.4¢	11400	1

View Market Depth

No.	Vol.	Price($)
1	42000	0.012
2	3999999	0.010
5	2072715	0.009
3	1186222	0.008
2	240000	0.007

Price($)	Vol.	No.
0.014	11400	1
0.015	801200	3
0.016	429958	1
0.017	321118	2
0.018	115942	2

Last trade - 16.12pm 04/10/2024 (20 minute delay)

AJX (ASX) Chart

Day chart unavailable

Share Price Calculation, page-3

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

BCI reaches close of funding facility for salt-first part of Mardie project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Buxton projects new graphite province discovery at WA Narryer play

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Share Price Calculation, page-3

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

BCI reaches close of funding facility for salt-first part of Mardie project

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

Buxton projects new graphite province discovery at WA Narryer play

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News